within 2 hours of one other for each patient to identify ureteral patency, the primary outcome for this study. Results from both imaging studies were reviewed in a blinded fashion by two experienced radiologists and compared.
INTRODUCTION AND OBJECTIVES:
We evaluate intervention rates and survival outcomes of complex renal cysts in a single center experience. Outcomes stratified by initial classification according to the Bosniak classification system. METHODS: We used a radiology data-mining system (Montage; Montage Healthcare Systems, Philadelphia, PA, USA) to retrospectively review the radiology database in an academic health center between 2001 and 2013 to identify all cases of "complex cyst." Primary end points were overall (OS) and cancer specific survival (CSS).
RESULTS: 248 patients were identified using the Montage system to have radiographic reports of complex renal cysts. Of these, 141 (56.9%), 86 (34.7%), and 21 (8.4%) had Bosniak 2F, 3 and 4 cysts, respectively. Median follow-up was 66.05AE54.24 months with an average of 3.61 scans (all modalities) per year. Of the 244 patients for whom we had follow-up, there were no cancerspecific deaths and overall mortality was 7.4%. Only 1 patient (4.7%) with a Bosniak 4 lesion at diagnosis developed metastases during follow-up. 20 patients underwent percutaneous biopsy of a solid nodule within the cyst; 7 (35%) were found to have renal cell carcinoma, and all of these patients received treatment. With regards to intervention, 6 (4.3%), 31 (36.0%) and 13 (61.9%) of the Bosniak 2F, 3 and 4 patients underwent either surgical or ablative intervention, respectively. Indication for intervention was predominantly age (median age: intervention 50.3AE14.6, no intervention 63.4AE13.3). Median time to intervention from initial identification was 6.45 months. Extirpative surgery with radical (17 patients, 34%) or partial nephrectomy (30 patients, 60%) was the predominant intervention, while 3 patients (6%) underwent ablation. While 4 patients (8.5%) had benign final pathology, the remainder had RCC: 23 (48.9%) clear cell RCC, 10 (21.2%) multilocular cystic RCC, 7 (14.9%) papillary type 1 RCC, 3 (6.4%) papillary type II RCC and 1 (2.1%) tubulocystic RCC. The majority (95.1%) were Fuhrman grade 1 or 2; 2 patients (4.9%) were Fuhrman grade 3. None of the patients undergoing intervention had evidence of recurrence during follow-up. Even when excluding patients undergoing intervention, CSS remained 100%.
CONCLUSIONS: Cancer-specific survival and overall survival for patients diagnosed with Bosniak 2F-4 complex renal cysts remains quite high; there were no cancer-specific deaths, even in the group that received no intervention. Reconsideration of management guidelines for complex renal cysts based on Bosniak classification system is warranted, particularly for Bosniak 3 cysts. METHODS: Men presented for prostate biopsy were randomized to receive ciprofloxacin 500mg B.I.D for 3days from the night of biopsy (group A), augmented prophylaxis using ciprofloxacin and single prebiopsy shot of 160mg gentamycin IM (group B) and rectal swab culture based prophylaxis (group C). Primary end point is occurrence of postprocedure sepsis[ge]2 of SIRS (systemic inflammatory response syndrome) criteria. Inflammatory markers were used for postprocedure screening; CRP (C reactive protein), ESR (Erythrocyte sedimentation rate) and TLC (total leucocyte count). Secondary endpoint is occurrence of FQ-R in the screened men. Men were assessed 2 weeks prior to biopsy, at time of biopsy and 2 weeks after.
Source of
RESULTS: Since November 2015, 258patients were randomized 89, 94 and 80 patients in groups A, B and C respectively. Baseline data was comparable among the 3 groups including prebiopsy urine culture with significant growth in 8 (8.9%), 8 (8.5%) and 10 (12%) in groups A, B and C respectively (P 0.6) and were treated before biopsy. Postprocedure fever occurred in 19 (21.3%), 9 (9.5%) and 8 (10%) in groups A, B and C respectively (P 0.03). Sepsis was reported in 5 (5.6%), 5 (5.3%) and 4 (5%) in groups A, B and C respectively (P 0.9) and 2 (2.2%) patients in group A required hospitalization. Figure 1 shows that the degree of change in TLC and ESR-1stH group was significantly more in group A than other groups (P 0.04 and 0.02 respectively). Urine culture 2 weeks after biopsy showed significant growth in 23 (25.8%), 5 (5.3%) and 11 (13.7%) in groups A, B and C respectively (P 0.002)Significant bacterial growth was noted in 62 (77.5%) out of 80 rectal swabs, FQ-R was reported in 55/62 (88.2%).
CONCLUSIONS: With increasing FQ-R, ciprofloxacin alone is not an optimal prophylactic approach. Augmented prophylaxis with single dose gentamycin is an effective approach. Targeted prophylaxis might be used when gentamycin is contraindicated.
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